Company Description
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally.
The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFβ TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies.
In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody.
The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011.
Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
| Country | United States |
| Founded | 1994 |
| IPO Date | Feb 4, 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 389 |
| CEO | Dr. Garo H. Armen Ph.D. |
Contact Details
Address: 3 Forbes Road Lexington, Massachusetts 02421 United States | |
| Phone | 781-674-4410 |
| Website | agenusbio.com |
Stock Details
| Ticker Symbol | AGEN |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001098972 |
| CUSIP Number | 00847G705 |
| ISIN Number | US00847G7051 |
| Employer ID | 06-1562417 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Garo H. Armen Ph.D. | Founder, Executive Chairman and Chief Executive Officer |
| Christine M. Klaskin | Vice President of Finance, Principal Financial Officer and Principal Accounting Officer |
| Dr. Steven J. O'Day M.D., Ph.D. | Chief Medical Officer |
| Craig Winter | Chief Information Officer |
| Zack Armen | Head of Investor Relations |
| Tracy Mazza Clemente | Chief People Officer |
| Dhan Chand | Scientific Director and Head of Drug Discovery |
| Alfred Dadson | Chief Manufacturing Officer |
| Eric Humes | Chief Quality Officer |
| Dr. Todd Jude Yancey M.D. | Member of Advisory Board and Chief Strategic Advisor |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 25, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 17, 2024 | 8-K | Current Report |
| Jun 14, 2024 | 8-K | Current Report |
| Jun 10, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| May 30, 2024 | 8-K | Current Report |
| May 7, 2024 | 8-K | Current Report |
| May 7, 2024 | 10-Q | Quarterly Report |
| May 7, 2024 | 8-K | Current Report |
| Apr 26, 2024 | ARS | Filing |
| Apr 26, 2024 | DEF 14A | Other definitive proxy statements |